Transfemoral TAVR Lowers Risk in Aortic Regurgitation

A randomized trial in China found the procedure plus medical therapy cut 1-year composite risk compared with medical therapy alone.

Updated on Nov. 12, 2026 in Heart Disease

Photorealistic view of a C-arm X-ray imaging system above an empty draped surgical table in a bright sterile operating room.
Researchers in China found transfemoral TAVR plus medical therapy cut one-year risk to 8.3% versus 24.8% for medical therapy alone in severe aortic regurgitation. AI Illustration. Upload story photo >

A randomized trial of 210 patients with severe aortic regurgitation found that transfemoral TAVR combined with guideline-directed medical therapy (GDMT) produced a lower 1-year primary endpoint rate than GDMT alone, at 8.3% versus 24.8%. The study was published online October 31, 2026, in Circulation.

Why it matters

Patients who are considered unsuitable for open-heart surgery, or who decline it, have had limited options for this condition. The findings suggest transfemoral TAVR may be a potential option for selected high-surgical-risk patients, though the authors caution against unrestricted off-label use.

The randomized trial of 210 patients reported a 1-year primary endpoint rate of 8.3% with TAVR plus GDMT versus 24.8% with GDMT alone. Early risks were higher with TAVR, including 9.2% major or life-threatening bleeding versus 0% and 20.2% new pacemaker implantation versus 2.0% at 30 days.

The players

Circulation

Circulation is a peer-reviewed journal published by the American Heart Association that is widely regarded as one of the leading cardiology publications.

The details

Researchers enrolled patients at multiple centers in China between 2021 and 2025, randomly assigning 109 patients to transfemoral TAVR using the VitaFlow valve plus GDMT and 101 to GDMT alone. Eligible patients were those whom local heart teams judged unsuitable for or difficult to treat with surgery, or who persistently declined it; both groups had no significant difference in all-cause death or disabling stroke.

Timeline

  1. 2021 to 2025: Patients enrolled at multiple centers in China.

  2. 1 year: Primary endpoint and functional outcomes assessed.

  3. 30 days: Bleeding and pacemaker implantation endpoints assessed.

  4. October 31, 2026: Study published online in Circulation.

Roadmap

The trial positions transfemoral TAVR as an alternative to standard surgical aortic valve replacement for patients who cannot or will not undergo open surgery. It builds on the established role of transcatheter valve procedures by testing them specifically in severe aortic regurgitation, a setting where the valve must be replaced rather than only opened.

For patients with severe aortic regurgitation who are not candidates for open surgery, this trial suggests a transcatheter option may reduce the risk of worsening heart failure within a year. However, the study also found higher rates of major bleeding and new pacemaker implantation early after the procedure, which patients should discuss with their heart team.

The takeaway

Patients weighing treatment for severe aortic regurgitation should ask their heart team whether they fit the profile studied here, and weigh the lower heart failure risk against early bleeding and pacemaker risks.

Further reading

For more background on related conditions and treatments, explore our Heart Disease coverage.

Source note: This article includes information reported by Medscape.